Bausch Health Companies Inc. (BHC) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $5.68. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BHC = $67.78 (+1093.3% from the current price, the stock appears undervalued). Analyst consensus target is BHC = $8 (+40.8% upside).
Valuation: BHC trades at a trailing Price-to-Earnings (P/E) of 12.5 (S&P 500 average ~25).
Financials: revenue is $10.3B, +8.3%/yr average growth. Net income is $155M, growing at +122.6%/yr. Net profit margin is 1.5% (thin). Gross margin is 68.3% (-2.6 pp trend).
Balance sheet: total debt is $21.2B with negative equity of -$553M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.47 (adequate). Debt-to-assets is 80.6%. Total assets: $26.3B.
Analyst outlook: 19 / 38 analysts rate BHC as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 83/100 (Pass), Past 25/100 (Fail), Health 25/100 (Fail), Moat 69/100 (Partial), Future 64/100 (Pass), Income 30/100 (Fail).
